Ocugen Balance Sheet Health
Financial Health criteria checks 4/6
Ocugen has a total shareholder equity of $40.6M and total debt of $2.8M, which brings its debt-to-equity ratio to 6.9%. Its total assets and total liabilities are $64.5M and $24.0M respectively.
Key information
6.9%
Debt to equity ratio
US$2.80m
Debt
Interest coverage ratio | n/a |
Cash | US$39.46m |
Equity | US$40.56m |
Total liabilities | US$23.98m |
Total assets | US$64.55m |
Recent financial health updates
Recent updates
Ocugen announces peer-reviewed publication on COVID-19 vaccine
Sep 14Ocugen initiated with Buy at Mizuho citing favorable setup ahead of key readout
Aug 23Ocugen Q2 2022 Earnings Preview
Aug 04Ocugen: A First Take
Jul 18Ocugen in renewed focus as FDA wants COVID boosters to fight Omicron variant
Jul 05Where Will Ocugen Stock Be In 5 Years?
Apr 27Ocugen: FDA Lifts Clinical Hold As Shares Sink - It May Be Worth Staying The Course
Feb 24Ocugen: The Life After COVID-19
Jan 23Financial Position Analysis
Short Term Liabilities: OCGN's short term assets ($43.0M) exceed its short term liabilities ($17.1M).
Long Term Liabilities: OCGN's short term assets ($43.0M) exceed its long term liabilities ($6.9M).
Debt to Equity History and Analysis
Debt Level: OCGN has more cash than its total debt.
Reducing Debt: OCGN had negative shareholder equity 5 years ago, but is now positive and has therefore improved.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: OCGN has less than a year of cash runway based on its current free cash flow.
Forecast Cash Runway: OCGN has less than a year of cash runway if free cash flow continues to reduce at historical rates of 37.2% each year